CJC-1295/Ipamorelin (10/10mg)

CJC-1295/Ipamorelin (10/10mg): Product Description

The CJC‑1295/Ipamorelin blend combines two chemically distinct research peptides investigated through complementary growth-hormone-associated signaling systems. CJC‑1295 No DAC, frequently identified as Modified GRF 1‑29, is a synthetic GHRH analog. Ipamorelin is a pentapeptide studied as a selective agonist of the growth hormone secretagogue receptor.

Laboratory research involving this blend may examine GHRH-receptor signaling, ghrelin-receptor interactions, intracellular cyclic AMP pathways and the relationship between two distinct receptor systems in controlled cellular models. Since each component maintains its individual molecular identity, the blend does not have one unified molecular formula or molecular weight.

The precise version of CJC‑1295 is important. CJC‑1295 with DAC and CJC‑1295 No DAC are structurally different materials and should not be treated as interchangeable. Molecular Edge should confirm that this product contains the No DAC version before publishing its specifications.

Experimental outcomes may depend on the component ratio, assay design, receptor expression and peptide stability. The product’s Certificate of Analysis should be reviewed to confirm the identity, quantity and purity of both components.

Research Specifications

CJC‑1295 No DAC

Molecular Formula: C152H252N44O42

Molecular Weight: Approximately 3,367.9 g/mol

Compound Type: Modified GHRH 1‑29 analog

Research Target: GHRH receptor

Ipamorelin

Molecular Formula: C38H49N9O5

Molecular Weight: Approximately 711.85 g/mol

CAS Number: 170851-70-4

Amino Acid Count: 5

Research Target: Growth hormone secretagogue receptor

Blend Presentation: 10 mg CJC‑1295 / 10 mg Ipamorelin

For Research Use Only. Not for human or animal consumption. Not intended for diagnostic or therapeutic use.